Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II
Clinical trial NCT03041324 · TERMINATED
Trial details
- NCT number
- NCT03041324
- Sponsor
- Sangamo Therapeutics
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-05-11
- Primary completion
- 2021-05-07
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.